Tocilizumab (Actemra)

Tocilizumab is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis.

It binds soluble as well as membrane bound interleukin-6 receptors, hindering IL-6 from exerting its pro-inflammatory effects.

It is administered through intravenous infusion every month or subcutaneously every 2 weeks.

In 2016, it sold €125 million in Europe.

It has an immunogenicity rate of 0-16%.

Labs that test for drug level: 

University of Tours
United Medix Labs

Labs that test for ADA titre: 

United Medix Labs